Tag: hemophilia
Sanofi: positive phase III data in hemophilia A
(CercleFinance.com) – Sanofi announces positive results from the pivotal phase III XTEND-1 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alpha in adults and adolescents aged 12 or over…
Fitusiran prophylaxis reduced bleeding by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor replacement or bypassing agent prophylaxis
Prophylaxis by fitusiran reduced bleeding by 61% in people with hemophilia A or B, with or without inhibitors, compared prior factor replacement prophylaxis or by agent short-circuiting A median annualized…
World Hemophilia Day: a difficult disease to diagnose
Yasmina Kattou edited by Wassila Belhacine 3:12 p.m., April 17, 2022 Hemophilia is a disease that causes blood clotting difficulties in people who suffer from it. It is a difficult…
Sanofi: limited increase after the positive results of the drug candidate in hemophilia A
By Jean-Baptiste André Published on 03/09/2022 at 2:00 p.m. Photo credit © Sanofi …
Sanofi: positive phase III data in hemophilia A – 03/09/2022 at 08:18
(CercleFinance.com) – Sanofi announces that the phase III study devoted to efanesoctocog alpha once a week in the treatment of hemophilia A has reached its primary endpoint and has allowed…
Sanofi: first positive data against hemophilia A – 03/09/2022 at 08:48
(AOF) – Sanofi’s pivotal study of efanesoctocog alpha met its primary endpoint and key secondary endpoints in the treatment of hemophilia A, “illustrating its superiority over prior anti-factor prophylaxis haemophiliac,”…